Outcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma
Sign Up to like & getrecommendations! Published in 2020 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2020.1810573
Abstract: ABSTRACT Objectives Metastatic squamous cell carcinoma anal cancer (SCCA) is rare. Prospective data recommends front-line platinum doublet combinations and second-line anti-programmed death-1 therapy. Standard therapy beyond these treatments are currently unknown. We evaluated anti-EGFR monoclonal… read more here.
Keywords: cell carcinoma; scca; squamous cell; egfr monoclonal ... See more keywords
Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal Antibodies
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14041052
Abstract: Simple Summary Increasing evidence suggests that circulating cell-free DNA (cfDNA) testing might allow for monitoring the response to anti-EGFR monoclonal antibodies in patients with metastatic colorectal carcinoma (mCRC). However, few data are available in treatment-naïve… read more here.
Keywords: metastatic colorectal; ras braf; braf mutations; egfr monoclonal ... See more keywords
Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with KRAS p.G13D Mutation
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms21176037
Abstract: The now clinically-used anti-epidermal growth factor receptor (EGFR) monoclonal antibodies have demonstrated significant efficacy only in patients with metastatic colorectal cancer (mCRC), with wild-type Kirsten rat sarcoma viral oncogene homolog (KRAS). However, no effective treatments… read more here.
Keywords: egfr monoclonal; colorectal cancer; antibody; anti egfr ... See more keywords